



**U.S. Department of
Health and Human Services**
Centers for Disease
Control and Prevention

Print Date: 9/19/24

Title: The National Antimicrobial Resistance Monitoring System for Enteric Bacteria (NARMS) and Select Isolate Response Initiative (SIRI)

Project Id: 0900f3eb8244160e

Accession #: NCEZID-NARMS-8/23/24-21dd3

Project Contact: Laura A Ford

Organization: NCEZID/DFWED/EDEB/NARMS

Status: **Pending Regulatory Clearance**

Intended Use: **Project Determination**

Estimated Start Date: 08/23/2024

Estimated Completion Date: 08/25/2036

CDC/ATSDR HRPO/IRB Protocol #:

OMB Control #:

Determinations

Determination	Justification	Completed	Entered By & Role
HSC: Does NOT Require HRPO Review	Not Research - Public Health Surveillance <i>45 CFR 46.102(l)(2)</i>	9/3/24	Peterson_James M. (iyr1) CIO HSC
PRA: PRA Applies		9/16/24	Vice_Rudith (nhr9) OMB / PRA

Description & Funding

Description

Priority: Standard

Date Needed: 09/26/2024

Priority Justification:

CDC Priority Area for this Project: Readiness and Response

Determination Start Date: 09/16/24

Description:

Each year, approximately 4.9 million bacterial enteric illnesses occur in the United States, resulting in an estimated 35,800 hospitalizations and 1,093 deaths. Most bacterial enteric infections are self-limited and do not require antibiotics, but antibiotics are indicated for patients with severe disease or risk factors for severe disease. The growing proportion of antimicrobial-resistant bacterial enteric infections limits treatment options and creates opportunities for resistance to spread to other pathogens. Extended-spectrum beta-lactamase-producing *Escherichia coli* and antimicrobial-resistant *Campylobacter*, nontyphoidal *Salmonella*, *Salmonella* serotype Typhi, and *Shigella* have been classified as serious public health threats, which require prompt and sustained action. The National Antimicrobial Resistance Monitoring System for Enteric Bacteria (NARMS) is a collaboration among CDC, the US Food and Drug Administration, the US Department of Agriculture, and state and local health departments, that monitors resistance in enteric bacteria. Antimicrobial resistance data can inform the development of public health interventions and policies designed to protect people from the threat of resistant enteric infections. Data can be collected through routine surveillance to measure antimicrobial resistance in bacteria isolated from people or through surveillance of antimicrobial resistance during outbreaks. Surveillance of resistance during outbreaks can help investigators identify the source of an outbreak or provide clues about the source of the outbreak. Investigations of outbreaks of resistant *Salmonella* traced to food-producing animals can show how animal and human health are linked. Additionally, to help focus efforts for preventing antimicrobial-resistant bacterial enteric illness, there is a need to monitor and assess risk factors and outcomes associated with resistance. State and local health departments routinely conduct patient interviews to investigate cases and outbreaks of illness caused by enteric pathogens. The interviews typically include demographics, clinical information such as symptoms, duration, severity, and treatment, and risk factor and exposure information, such as recent travel, food consumption, and animal contact. For patients with bacterial enteric infections that have concerning antimicrobial resistance, the CDC NARMS team would like to request information from initial patient interviews. If additional information would further enhance the existing surveillance data provided by health departments, the CDC NARMS team may want to request medical and pharmacy records, as well as request or perform supplemental interviews, additional phenotypic and genotypic testing on isolates, shopper records, food, environmental, or animal sampling, or field investigations if needed. This enhanced surveillance will both monitor for and assess emerging antimicrobial resistance of concern and inform public health response and mitigation efforts.

IMS/CIO/Epi-Aid/Lab-Aid/Chemical Exposure Submission: No

IMS Activation Name: Not selected

Submitted through IMS Clearance Matrix: Not selected

Primary Scientific Priority: Not selected

Secondary Scientific Priority (s): Not selected

Task Force Responsible: Not selected

CIO Emergency Response Name: Not selected

Epi-Aid Name: Not selected

Lab-Aid Name: Not selected

Assessment of Chemical Exposure Name: Not selected

Goals/Purpose

NARMS routine and outbreak surveillance: The goal of NARMS routine and outbreak surveillance is to track and report antimicrobial resistance data on enteric bacteria collected from humans through routine frequency-based surveillance and from outbreaks associated with contaminated foods, contact with animals, and human to human transmission. SIRI: The goal of the select isolate response initiative (SIRI) is to enhance public health surveillance and reporting of antibiotic-resistance threats. Characterizing exposures, risk factors, and sources of illness for resistant enteric infections can inform efforts to prevent additional infections and the spread of disease. Additionally, describing risk factors and the clinical outcomes of resistant enteric infections may improve clinical education and awareness of emerging health threats.

Objective:

NARMS routine and outbreak surveillance: Objectives include, 1. Detect emerging trends of resistance. 2. Link enteric illnesses (resistant and susceptible) to specific sources and risk factors. 3. Monitor for emerging genetic mechanisms that confer resistance and assess their spread among enteric bacteria. 4. Collaborate on investigation of enteric disease, including multistate foodborne outbreaks. 5. Educate consumers about foodborne antimicrobial threats and food safety practices that protect against these threats. 6. Guide public health priorities. 7. Provide information and recommendations that promote the judicious use of antimicrobial agents. SIRI: The objective is to obtain information about persons with bacterial enteric infections that have concerning resistance, their infections, and their environments and food sources to identify potential exposures and clinical consequences of infection. This includes obtaining information from: 1. Initial interview data (e.g., demographics, recent travel, food consumption, and animal contact) 2. Supplementary interview data (e.g., more focused questions about travel, food consumption, and/or animal contact) 3. Medical and pharmacy records 4. Additional testing on isolates (e.g., long-read sequencing, antimicrobial susceptibility testing) 5. Shopper records, food, environmental, or animal testing and field investigations (e.g., request swabs of reptile environments or request collection of leftover foods of interest) 6. Additional testing for patients or contacts (e.g., stool culture, CIDT, or other diagnostic test for screening of symptomatic or asymptomatic contacts, patients with ongoing symptoms, post-symptomatic patients suspected of carriage)

Does your project measure health disparities among populations/groups experiencing social, economic, geographic, and/or environmental disadvantages?: No

Does your project investigate underlying contributors to health inequities among populations /groups experiencing social, economic, geographic, and/or environmental disadvantages?: No

Does your project propose, implement, or evaluate an action to move towards eliminating health inequities?: Yes

Activities or Tasks:

New Collection of Information, Data, or Biospecimens ; Secondary Data or Specimen Analysis ; Purchase, Use, or Transfer of Information, Data, Biospecimens or Materials

Target Populations to be Included/Represented:	General US Population
Tags/Keywords:	Drug Resistance, Bacterial ; Public Health Surveillance ; Salmonella ; Campylobacter ; Shigella ; Shiga-Toxigenic Escherichia coli ; Vibrio
CDC's Role:	Activity originated and designed by CDC staff, or conducted at the specific request of CDC, or CDC staff will approve study design and data collection as a condition of any funding provided ; CDC employees or agents will obtain data by intervening or interacting with participants ; CDC employees or agents will obtain or use identifiable (including coded) private data or biological specimens ; CDC employees will participate as co-authors in presentation(s) or publication(s)
Method Categories:	Exposure Investigation; Genetic Sequencing; Record Review; Secondary Data Analysis; Secondary Specimen Analysis; Surveillance Support
Methods:	NARMS routine and outbreak surveillance: State and large urban public health departments submit Salmonella, Campylobacter, Shigella, E. coli, and Vibrio isolates to CDC for antimicrobial susceptibility testing according to a preestablished sampling strategy (routine surveillance) or in response to request by investigators (outbreak surveillance). Isolates that have undergone whole genome sequencing (WGS), either by state health departments or CDC and submitted to PulseNet, are also screened for predicted resistance based on the presence of genes and mutations known to confer antimicrobial resistance. Health departments submit limited metadata along with each isolate (e.g., age, sex, and state of residence). SIRI: CDC investigators identify isolates with concerning resistance patterns based on AST results or WGS data uploaded to PulseNet. Investigators follow up with epidemiologists at state or local health department to obtain additional patient and isolate information, as described below. Depending on the resistance pattern and available information, additional epidemiological records (including primary interview records, medical records, or pharmacy records) and additional laboratory testing (of the original isolate, or environmental or food testing) could be requested. NARMS routine and outbreak surveillance: 54 participating state and local public health departments send a sample of enteric bacterial isolates for routine surveillance and a sample of outbreak isolates (when requested) for outbreak surveillance to CDC. Basic metadata (e.g., age, gender, and state of residence) are submitted with the isolates. State and local health departments submit data, or the CDC team enters data, to the NARMS data system by one of two methods: by directly entering the data via a web-based entry form and submitting that data to CDC, or by field mapping an electronic file to NARMS form fields and uploading data en masse to CDC. The CDC NARMS laboratory staff perform broth microdilution antimicrobial susceptibility testing on these isolates using the the Sensititre# semiautomated platform, and the CDC team enters the numerical results into the NARMS system using a SWIN export file (.csv) captured from the laboratory testing device. The SWIN export file and contents must meet NARMS system validation requirements. Additionally, public health laboratories, with state and local health departments, submit sequence data for enteric bacteria isolates to PulseNet. PulseNet has received a non-research determination for their work. Data from PulseNet to NARMS go through the Data Broker, an internal web service that allows the NARMS application to access additional data shared by PulseNet. The NARMS data system receives information nightly on antimicrobial resistance genes, mutations, and plasmids gleaned from whole genome sequence data and limited demographic information submitted to PulseNet. NARMS CDC team members with approval rights review and determine acceptability of laboratory data, predicted resistance data, and demographic data fields through approval interfaces built into the NARMS data system. As only basic metadata is available in the NARMS data system, isolate resistance data may be linked with additional patient epidemiological data collected by other CDC public health surveillance systems to further assess and respond to antimicrobial resistant infections and outbreaks. NARMS data may be linked with data from the National Surveillance Team (OMB Control Number 0920-0728, expiration 3/31/2027), FoodNet (Exempt Research Protocol 6182, reviewed June 23, 2023), the National Outbreak Reporting System (NORS) (OMB Control Number 9020-1304, expiration 8/31/2025), or with data collected as part of a cluster or outbreak investigation and stored in SEDRIC (OMB Control number 0920-0997, expiration 9/30/2026). SIRI: For isolates with concerning resistance, CDC investigators will contact epidemiologists at state or local health departments to request information from the state or local health department#s case investigation, including copies of state/local case report forms which typically capture demographic information, illness information (symptoms, hospitalization, treatment, outcomes), and other exposure or risk factor information (travel, food history, animal and
Collection of Info, Data or Biospecimen:	

water exposures, other risk factor information). We have reached the character limit - please see the attachment for more information on data and biospecimen collection.

Approved NARMS routine and outbreak surveillance data will be released back to the submitting state or local public health department. Routine and outbreak surveillance data with limited demographic data may also be made available online (e.g., NARMS Now: Human Data, BEAM Dashboard, FDA's Integrated data platform, Sanford Guide), in agency reports, or outbreak web postings. Additionally, information about resistant infections, including risk factors or exposures and outcomes, may be summarized and disseminated to support public health activities and other infection control and prevention efforts; inform various stakeholders; inform the establishment and revision of criteria used to interpret antimicrobial susceptibility tests; and educate clinical management. The information may be used in public health reports and presentations; peer-reviewed publication; web posts or other health messaging to health care providers, clinical and public health laboratories, and the public; and communications with other stakeholders.

Expected Use of Findings/Results and their impact:

Could Individuals potentially be identified based on Information Collected? Yes

Will PII be captured (including coded data)? Yes

Does CDC have access to the identifiers (including coded data)?: Yes

Is this project covered by an Assurance of Confidentiality? No

Does this activity meet the criteria for a Certificate of Confidentiality (CoC)? No

Is there a formal written agreement prohibiting the release of identifiers? No

Funding

Funding Type	Funding Title	Funding #	Original Budget Yr	# Years Award	Budget Amount
CDC Cooperative Agreement	ELC Cooperative Agreement				

HSC Review

Regulation and Policy

Do you anticipate this project will require review by a CDC IRB or HRPO? No

Estimated number of study participants

Population - Children

Protocol Page #:

Population - Minors

Protocol Page #:

Population - Prisoners

Protocol Page #:

Population - Pregnant Women

Protocol Page #:

Population - Emancipated Minors

Protocol Page #:

Suggested level of risk to subjects

Do you anticipate this project will be exempt research or non-exempt research

Requested consent process wavers

Informed consent for adults No Selection

Children capable of providing assent No Selection

Parental permission No Selection

Alteration of authorization under HIPAA Privacy Rule No Selection

Requested Waivers of Documentation of Informed Consent

Informed consent for adults No Selection

Children capable of providing assent No Selection

Parental permission No Selection

Consent process shown in an understandable language

Reading level has been estimated No Selection

Comprehension tool is provided	No Selection
Short form is provided	No Selection
Translation planned or performed	No Selection
Certified translation / translator	No Selection
Translation and back-translation to/from target language(s)	No Selection
Other method	No Selection

Clinical Trial

Involves human participants	No Selection
Assigned to an intervention	No Selection
Evaluate the effect of the intervention	No Selection
Evaluation of a health related biomedical or behavioral outcome	No Selection
Registerable clinical trial	No Selection

Other Considerations

Exception is requested to PHS informing those bested about HIV serostatus	No Selection
Human genetic testing is planned now or in the future	No Selection
Involves long-term storage of identifiable biological specimens	No Selection
Involves a drug, biologic, or device	No Selection
Conducted under an Investigational New Drug exemption or Investigational Device Exemption	No Selection

Institutions & Staff

Institutions

Will you be working with an outside Organization or Institution? Yes

Institution	FWA #	FWA Exp Date	Funding	Funding Restriction Amount
All US State Health Departments			ELC Cooperative Agreement	

Institution	Funding Restriction Percentage	Funding Restriction Reason	Funding Restriction has been Lifted
All US State Health Departments			

Institution	Institution Role(s)	Institution Project Title	Institution Project Tracking #	Prime Institution
All US State Health Departments	Obtaining Consent; Obtaining, Storing or Transferring Identifiable Private Information or Identifiable Biospecimens			

Institution	Regulatory Coverage	IRB Review Status
All US State Health Departments	IRB Review is Not Required	

Institution	Registered IRB	IRB Registration Exp. Date	IRB Approval Status
All US State Health Departments			

Institution	IRB Approval Date	IRB Approval Exp. Date	Relying Institution IRB
All US State Health Departments			

Staff

Staff Member	SIQT Exp. Date	CITI Biomedical Exp. Date	CITI Social & Behavioral Exp. Date	CITI Good Clinical Practice Exp. Date	CITI Good Laboratory Practice Exp. Date	Staff Role	Email	Phone	Organization
Beth Karp	08/19 /2026	12/01/2024				Co-Investigator	jyo2@cdc.gov	404-639-5097	NARMS Team
Caroline Snyder	07/27 /2026		07/27/2025			Co-Investigator	qmm3@cdc.gov	404-718-1673	NARMS Team
Felicita Medalla	06/12 /2025	01/02/2022				Co-Investigator	fhm1@cdc.gov	404-639-3426	NARMS Team
HAIMANOT KEBBEDE	08/09 /2026					Co-Investigator	rcu1@cdc.gov	404-718-8448	National Surveillance Team
Hayat Caidi	07/11 /2026	07/27/2021				Co-Investigator	foi0@cdc.gov	404-639-0766	NATIONAL ANTIMICROBIAL RESISTANCE SURVEILLANCE TEAM
Jared Reynolds	09/01 /2026	12/26/2021	12/26/2021	12/26/2021		Co-Investigator	uvz6@cdc.gov	404-639-3519	NARMS Team
Jason Folster	06/26 /2026	02/28/2027				Co-Investigator	gux8@cdc.gov	404-639-8	NATIONAL ANTIMICROBIAL RESISTANCE SURVEILLANCE TEAM
Jean Whichard	12/14 /2025	12/14/2025				Co-Investigator	zyr3@cdc.gov	404-639-2000	ENTERIC DISEASES LABORATORY BRANCH
Laura Cooley	11/09 /2026		12/13/2021			Co-Investigator	whz3@cdc.gov	404-639-2096	NARMS Team
Laura Ford	05/12 /2026	06/23/2026	06/26/2026			Co-Investigator	qdz4@cdc.gov	404-718-1141	NARMS Team
Louise Francois Watkins	08/28 /2026		02/17/2025	02/20/2025		Co-Investigator	hvu9@cdc.gov	404-639-4755	NARMS Team
Meseret	08/09					Co-	vk12@cdc.	404-	

Birhane	/2026	09/02/2027				Investigator	gov	639-2775	NARMS Team
Naeemah Logan	09/12/2026	12/31/2021				Co-Investigator	nqz8@cdc.gov	404-718-6837	NARMS Team

Data

DMP

Proposed Data Collection Start Date: 8/23/24

Proposed Data Collection End Date: 8/25/36

Proposed Public Access Level: Restricted

Restricted Details:

Data Use Type: Other - Data Use Agreement and Non-Disclosure Agreement

Data Use Type URL: https://wwwn.cdc.gov/NARMS/Landing_Pages/LandingPageCDCAdmin.aspx; <https://dcipher.cdc.gov/>

Data Use Contact: narms@cdc.gov; sedric@cdc.gov

Public Access Justification: Only listed staff and those with access to the NARMS Data System or SEDRIC will have access to the data. However, an aggregate summary of the data or de-identified data may be provided publicly (e.g., NARMS Now). If other individuals inside or outside of CDC request this information, they will be referred to narms@cdc.gov or sedric@cdc.gov or to state/local health departments to request access.

How Access Will Be Provided for Data: Data collected will be stored in the NARMS data system, on a secure shared drive, or in SEDRIC. Records will be coded to protect patient privacy and confidentiality. State health departments will retain access to all information from their respective states including keys to coded data (keys will not be shared to CDC). No data will be accessed or used by anyone who is not working on this project or does not have access to the NARMS system or SEDRIC. If other individuals inside or outside of CDC request this information, they will be referred to narms@cdc.gov, sedric@cdc.gov, or state/local health departments for access.

Plans for Archival and Long Term Preservation: NARMS routine and outbreak surveillance: Isolate metadata and resistance data are stored in the NARMS data system, which is a web application with two distinct servers hosting the web application and relational database management system. These servers are physically and logically separated from each other. Users of the system consist of both external state users and internal CDC NARMS users. External users access the system by passing through the CDC firewall while internal users access the system from within the firewall. CDC is going through a data modernization initiative, and as part of that initiative, the NARMS application is currently being refactored for relocation from on-premises servers to the cloud by November 1, 2024. Any isolates submitted to CDC will be stored indefinitely in the Enteric Diseases Laboratory Branch#s (EDLB) freezer collections along with all other isolates per EDLB and CDC policy. Audit trail for isolate location and final disposition are captured in the NARMS system. SIRI: Questionnaire data will be transmitted to CDC through via fax, encrypted email, or a secure data sharing platform. Supplementary

questionnaires will be stored on the CDC shared drive. Data will be entered into a secure database (e.g., Excel, Epi Info, RedCap, SEDRIC) stored on the CDC shared drive or share point and analyzed by CDC. Biospecimen data will be linked with questionnaire data by matching isolate information in the NARMS data system with questionnaire data by isolate identifier. Data will be stored at state or local health departments according to state protocols. Coded information will be stored at CDC in folders on a secure share drive or in SEDRIC.

Spatiality

Spatiality (Geographic Locations) yet to be added

Dataset

Dataset Title	Dataset Description	Data Publisher /Owner	Public Access Level	Public Access Justification	External Access URL	Download URL	Type of Data Released	Collection Start Date	Collection End Date
Dataset yet to be added...									

Supporting Info

Current	CDC Staff Member and Role	Date Added	Description	Supporting Info Type	Supporting Info
	Peterson_James M. (iyr1) CIO HSC	09/03/2024	N/A	HS Research Determination Memo	090324LF-NR-signed.pdf
	Ford_Laura (qdz4) Project Contact	08/30/2024	Revised protocol.	Protocol	NARMS Project Determination Request_Aug30clean.docx
	Peterson_James M. (iyr1) CIO HSC	08/29/2024	HSC added comments and edits using tracked changes.	Protocol	NARMS Project Determination Request_Aug19 HSC edits and comments.docx
Current	Ford_Laura (qdz4) Project Contact	08/23/2024	Metadata collected with isolate submission.	Other-Metadata collected	A. NARMS Metadata&logsheet Screen grab.docx
Current	Ford_Laura (qdz4) Project Contact	08/23/2024	SIRI Module 1	Data Collection Form	Form 5 - NARMS SIRI Module 1.docx
Current	Ford_Laura (qdz4) Project Contact	08/23/2024	SIRI Module 2	Data Collection Form	Form 6 - NARMS SIRI Module 2.docx
Current	Ford_Laura (qdz4) Project Contact	08/23/2024	NARMS Umbrella Project Determination Request	Protocol	NARMS Project Determination Request_Aug19.docx
Current	Ford_Laura (qdz4) Project Contact	08/23/2024	SIRI Module 3	Data Collection Form	Form 7 - NARMS SIRI Module 3.docx
Current	Ford_Laura (qdz4) Project Contact	08/23/2024	SIRI Module 4	Data Collection Form	Form 8 - NARMS SIRI Module 4.docx
Current	Ford_Laura (qdz4) Project Contact	08/23/2024	SIRI Module 5	Data Collection Form	Form 9 - NARMS SIRI Module 5.docx
Current	Ford_Laura (qdz4) Project Contact	08/23/2024	Verbal consent for additional samples.	Consent Form	G. Verbal Consent - samples.docx



U.S. Department of Health and Human Services
Centers for Disease Control and Prevention